首页> 外文期刊>Drug Design, Development and Therapy >Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection
【24h】

Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection

机译:新型抗微生物和抗炎短肽在耐甲氧西林金黄色葡萄球菌(MRSA)皮肤感染的小鼠模型中的功效

获取原文
       

摘要

Abstract: The therapeutic efficacy of two novel short antimicrobial and anti-inflammatory peptides (RR and RRIKA) was evaluated in a mouse model of staphylococcal skin infection. RR (2%) and RRIKA (2%) significantly reduced the bacterial counts and the levels of proinflammatory cytokines, tumor necrosis factor (TNF)-α, and interleukin (IL)-6, in methicillin-resistant Staphylococcus aureus USA 300-0114 skin lesions. Furthermore, the combined therapy of RRIKA (1%) and lysostaphin (0.5%) had significantly higher antistaphylococcal and anti-inflammatory activity compared to monotherapy. This study supports the potential use of these peptides for topical treatment of methicillin-resistant Staphylococcus aureus skin infections.
机译:摘要:在葡萄球菌皮肤感染的小鼠模型中评估了两种新型的短抗菌和消炎肽(RR和RRIKA)的治疗效果。在耐甲氧西林的金黄色葡萄球菌美国300-0114中,RR(2%)和RRIKA(2%)显着降低了细菌数量以及促炎细胞因子,肿瘤坏死因子(TNF)-α和白介素(IL)-6的水平皮损。此外,与单一疗法相比,RRIKA(1%)和溶葡萄球菌素(0.5%)的联合疗法具有明显更高的抗葡萄球菌和抗炎活性。这项研究支持这些肽在局部治疗耐甲氧西林金黄色葡萄球菌皮肤感染中的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号